House Committee Chair Cites Resistance Concerns in Animal Drug

House Rules Committee Chair writes to the FDA to suggest the rejection of an animal drug due to concerns about causing human resistance to similar drugs.

Published on: Jan 11, 2007

The Food and Drug Administration should follow it's scientific advisory committee's recommendation and reject the animal drug cefquinome, U.S. Rep. Louise Slaughter, D-N.Y., said in a letter to the FDA.

Slaughter, the Chair of the House Rules Committee, says the use of the drug, used to treat life-threatening infections in animals, could cause resistance to similar drugs in humans.

"Given the recent outbreaks of E. coli and other food borne illnesses across the nation, it is hardly the time to ignore the advice of scientists, and potentially impair our ability to treat deadly infections," Slaughter says.

The FDA's Veterinary and Medical Advisory Committee recommended on September 25 against FDA approval of cefquinome in cattle over concerns that it could make similar drugs less effective in humans.

The drug's manufacturer, Intervet, has suggested it intends to continue to seek approval for the drug and has not withdrawn its applications to the FDA.